Peptide
Cerluten
Cerluten (A-5, cerebral cortex peptide complex)
A brain-derived peptide complex from the Khavinson group in Saint Petersburg. Marketed as a broad CNS bioregulator. Human evidence sits almost entirely inside a single Russian research lineage.
Summary Does Cerluten help protect memory and slow age-related brain decline? Show / hide ↓
Cerluten is an extract from cow brain tissue containing short protein fragments called peptides. It is marketed for memory, reaction time, the body’s daily rhythm, and age-related cognitive decline. Small studies from one Russian research group have reported changes in brain electrical activity and other aging-related markers, but independent researchers have rarely repeated these findings. There are no modern placebo-controlled human trials listed on ClinicalTrials.gov, and longer lifespan in mice does not show that it helps people. A typical course contains 60 capsules of 215 mg, and users often take it in cycles, but this practice has not been properly tested.
What this means for you: Cerluten has a plausible theory behind it, but reliable evidence in people is lacking. It is not enough evidence to buy this for memory or longevity.
weak evidenceCerluten is one of the wide-spectrum products in the Khavinson bioregulator line. Where Cortagen is the isolated tetrapeptide AEDP, Cerluten is the broader tissue extract from bovine cortex, sold as a 60-capsule course of 215 mg capsules by RUPharma and similar Russian suppliers.
The theoretical model, developed at the Saint Petersburg Institute of Bioregulation and Gerontology since the late 1970s, is that short peptides isolated from a given organ enter the cell nucleus, bind DNA and histones, and re-tune gene expression in aged tissue toward a younger baseline. For the brain, that is claimed to mean better memory, faster reaction time, restored circadian rhythm, and slower cognitive decline in older adults.
The evidence base is real, and narrow. Vladimir Khavinson and colleagues have published dozens of studies since the 1980s, mostly in Russian gerontology journals, some in indexed English-language journals. Reported endpoints include improved EEG patterns in dementia patients, reduced lymphocyte chromatin condensation in elderly subjects, and increased median lifespan in mice. Very little of this work has been independently replicated outside the original research consortium. Rigorous placebo-controlled, industry-neutral human trials are essentially absent.
Inside the biohacking community, Cerluten is sometimes stacked with Endoluten (pineal) and Vladinox or Vladonix (thymus) as a so-called first-class stack, with the argument that hitting three master regulators at once produces synergistic effects. That claim has not been tested against a placebo group anywhere in the mainstream literature.
Our position: Cerluten sits at Tier 5. There is a coherent mechanistic story, decades of Russian-language work behind it, and a following inside the anti-aging community. There is also almost no independent human trial evidence and no regulatory approval for the claimed longevity benefits. Cyclic dosing (10 to 20 days on, several months off) is the standard practice among users.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.